EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling

Asif Ali, Dawood Khan, Ananyaa Sridhar, Vaibhav Dubey, Andrei I. Tarasov, Peter R. Flatt, Nigel Irwin

Frontiers in Endocrinology · 18.11.2026 · 17

DOI: 10.3389/fendo.2026.2006139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 18.11.2026. Verfasst von Asif Ali und 6 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ulster University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Glicentin (GLIC) is a major secretory product of intestinal L-cells whose physiological actions remain unclear. Circulating GLIC increases after gastric bypass and is associated with metabolic improvement. We investigated whether GLIC exerts integrated effects on beta-cell function and metabolism, comparing its signalling profile with GLP-1 and oxyntomodulin (OXM).

Methods

The effects of the three peptides on glucose tolerance, plasma insulin and food intake were assessed in vivo , alongside peptide stability in mouse plasma. Insulin secretion was measured in isolated islets, while real-time cAMP and cytosolic Ca² + dynamics were monitored using fluorescent sensors. Receptor involvement was examined using pharmacological antagonists and stably expressing cell lines.

Results

GLIC was highly protease-resistant, with no detectable degradation after 4 h in mouse plasma, unlike OXM and GLP-1. In mice, GLIC improved glucose tolerance, enhanced glucose-stimulated insulin secretion and reduced food intake, with effects broadly comparable to GLP-1 and OXM. GLIC stimulated insulin secretion from murine islets and BRIN-BD11 cells at concentrations ≥10 nmol/L and increased islet-cell cAMP and cytosolic Ca² + . Effects were attenuated by GLP-1R and GIPR blockade, with additional GCGR involvement. Accordingly, GLIC stimulated cAMP through all three receptors. GLIC also promoted beta-cell proliferation and reduced cytokine-induced apoptosis.

Conclusion

GLIC exerts integrated metabolic and beta-cell effects despite low receptor potency. Its marked plasma stability and distinct signalling profile suggest that receptor potency alone does not predict biological activity. GLIC warrants further investigation in human and disease-relevant models.

Förderung

  • Ulster University

Zitieren

APA

Ali, A., Khan, D., Sridhar, A., Dubey, V., Tarasov, A. I., Flatt, P. R., & Irwin, N. (2026). Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2006139

Vancouver

Ali A, Khan D, Sridhar A, Dubey V, Tarasov AI, Flatt PR, et al. Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2006139

BibTeX
@article{Ali2026,
  author = {Ali, Asif and Khan, Dawood and Sridhar, Ananyaa and Dubey, Vaibhav and Tarasov, Andrei I. and Flatt, Peter R. and Irwin, Nigel},
  title = {Glicentin is enzymatically stable, inhibits feeding and improves glucose tolerance and beta-cell function through GLP-1, GIP and glucagon receptor signalling},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.2006139}
}
Kostenlos starten →